TLC Biopharmaceuticals, based in South San Francisco, CA, is a leading company dedicated to the development of novel nanomedicines utilizing their proprietary LipAD lipid-assembled delivery system. Their focus on pain management, ophthalmology, oncology, and infectious diseases aims to reduce toxicity and improve efficacy through sustained release and targeted deliveries.
With a robust pipeline of early- to late-stage programs, TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with unique properties. Their innovative technology platforms, such as BioSeizer and NanoX, drive the development of longer-lasting, more effective medicines for a sustainable environment and improved patient outcomes.
Generated from the website